Eliezer Flescher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eliezer Flescher has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Ronit Rotem
Department of Human Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
3 shared publicationsA Heyfets
Department of Human Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
2 shared publicationsDorit Reischer
Tel Aviv University
2 shared publicationsNatalia Goldin
Department of Human Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
2 shared publicationsOrit Fingrut
Department of Human Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
2 shared publicationsA Israelson
Department of Human Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
1 shared publication
Latest Publications
- 20 June 2017
- Published by Springer Nature
- p. 2371-2374
Jasmonates in Cancer Therapy
- 23 November 2015
- Published by Springer Nature
- p. 1-4
Jasmonates in Cancer Therapy
- 1 January 2011
- Published by Springer Nature
- p. 1923-1926
Jasmonates in Cancer Therapy
- 16 September 2010
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 68 (7) , 1269-1281
Plant ribosome-inactivating proteins type II induce the unfolded protein response in human cancer cells
Cytotoxic ribosome-inactivating proteins (RIPs) of type II such as ricin were investigated as anti-cancer agents, but also pose a threat as biological weapons. The molecular mechanism leading to their toxic effects is, however, not yet clear. The current paradigm, which states that the irreversible depurination of 28S rRNA results in a general translational arrest eventually leading to cell death, has been questioned. Using micro-array, qRT-PCR and Western blot, we identified the unfolded protein response (UPR), a cellular mechanism activated in response to endoplasmic reticulum stress, that is induced in HCT116 and MDA-MB-231 cells exposed to the plant type II RIPs ricin, riproximin and volkensin. Apoptosis was induced by concentrations at which translation of UPR-related genes still occurred, despite concomitant ribosomal depurination. We conclude that UPR induction represents a model that better describes the cellular effects of RIP exposure at concentrations at which selected proteins are translated despite ribosomal depurination.
- 16 September 2010
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 68 (7) , 1269-1281
Plant ribosome-inactivating proteins type II induce the unfolded protein response in human cancer cells
Cytotoxic ribosome-inactivating proteins (RIPs) of type II such as ricin were investigated as anti-cancer agents, but also pose a threat as biological weapons. The molecular mechanism leading to their toxic effects is, however, not yet clear. The current paradigm, which states that the irreversible depurination of 28S rRNA results in a general translational arrest eventually leading to cell death, has been questioned. Using micro-array, qRT-PCR and Western blot, we identified the unfolded protein response (UPR), a cellular mechanism activated in response to endoplasmic reticulum stress, that is induced in HCT116 and MDA-MB-231 cells exposed to the plant type II RIPs ricin, riproximin and volkensin. Apoptosis was induced by concentrations at which translation of UPR-related genes still occurred, despite concomitant ribosomal depurination. We conclude that UPR induction represents a model that better describes the cellular effects of RIP exposure at concentrations at which selected proteins are translated despite ribosomal depurination.
- Open Access
- 5 January 2010
- Published by Springer Nature in Malaria Journal
- Vol. 9 (1) , 5
Schistosoma mansoni infection reduces the incidence of murine cerebral malaria
Background: PlasmodiumandSchistosomaare two of the most common parasites in sub-tropical areas. Deregulation of the immune response toPlasmodium falciparum, characterized by a Th1 response, leads to cerebral malaria (CM), while a Th2 response accompanies chronic schistosomiasis.Methods: The development of CM was examined in mice with concomitantSchistosoma mansoniandPlasmodium bergheiANKA infections. The effect of S.mansoniegg antigen injection on disease development and survival was also determined. Cytokine serum levels were estimated using ELISA. Statistical analysis was performed using t-test.Results: The results demonstrate that concomitantS. mansoniandP. bergheiANKA infection leads to a reduction in CM. This effect is dependent on infection schedule and infecting cercariae number, and is correlated with a Th2 response. Schistosomal egg antigen injection delays the death of Plasmodium-infected mice, indicating immune involvement.Conclusions: This research supports previous claims of a protective effect of helminth infection on CM development. The presence of multiple parasitic infections in patients from endemic areas should therefore be carefully noted in clinical trials, and in the development of standard treatment protocols for malaria. Defined helminth antigens may be considered for alleviation of immunopathological symptoms.
- 5 January 2010
- Published by Springer Nature in Malaria Journal
- Vol. 9 (1) , 5
Open AccessSchistosoma mansoni infection reduces the incidence of murine cerebral malaria
Background: PlasmodiumandSchistosomaare two of the most common parasites in sub-tropical areas. Deregulation of the immune response toPlasmodium falciparum, characterized by a Th1 response, leads to cerebral malaria (CM), while a Th2 response accompanies chronic schistosomiasis.Methods: The development of CM was examined in mice with concomitantSchistosoma mansoniandPlasmodium bergheiANKA infections. The effect of S.mansoniegg antigen injection on disease development and survival was also determined. Cytokine serum levels were estimated using ELISA. Statistical analysis was performed using t-test.Results: The results demonstrate that concomitantS. mansoniandP. bergheiANKA infection leads to a reduction in CM. This effect is dependent on infection schedule and infecting cercariae number, and is correlated with a Th2 response. Schistosomal egg antigen injection delays the death of Plasmodium-infected mice, indicating immune involvement.Conclusions: This research supports previous claims of a protective effect of helminth infection on CM development. The presence of multiple parasitic infections in patients from endemic areas should therefore be carefully noted in clinical trials, and in the development of standard treatment protocols for malaria. Defined helminth antigens may be considered for alleviation of immunopathological symptoms.
- Open Access
PI3K/Akt Pathway Activation Attenuates the Cytotoxic Effect of Methyl Jasmonate Toward Sarcoma Cells
- 14 April 2008
- Published by Springer Nature in Oncogene
- Vol. 27 (34) , 4636-4643
Methyl jasmonate binds to and detaches mitochondria-bound hexokinase
Cellular bio-energetic metabolism and mitochondria are recognized as potential targets for anticancer agents, due to the numerous relevant peculiarities cancer cells exhibit. Jasmonates are anticancer agents that interact directly with mitochondria. The aim of this study was to identify mitochondrial molecular targets of jasmonates. We report that jasmonates bind to hexokinase and detach it from the mitochondria and its mitochondrial anchor—the voltage-dependent anion channel (VDAC), as judged by hexokinase immunochemical and activity determinations, surface plasmon resonance analysis and planar lipid bilayer VDAC-activity analysis. Furthermore, the susceptibility of cancer cells and mitochondria to jasmonates is dependent on the expression of hexokinase, evaluated using hexokinase-overexpressing transfectants and its mitochondrial association. Many types of cancer cells exhibit overexpression of the key glycolytic enzyme, hexokinase, and its excessive binding to mitochondria. These characteristics are considered to play a pivotal role in cancer cell growth rate and survival. Thus, our findings provide an explanation for the selective effects of jasmonates on cancer cells. Most importantly, this is the first demonstration of a cytotoxic mechanism based on direct interaction between an anticancer agent and hexokinase. The proposed mechanism can serve to guide development of a new selective approach for cancer therapy.
- 14 April 2008
- Published by Springer Nature in Oncogene
- Vol. 27 (34) , 4636-4643
Methyl jasmonate binds to and detaches mitochondria-bound hexokinase
Cellular bio-energetic metabolism and mitochondria are recognized as potential targets for anticancer agents, due to the numerous relevant peculiarities cancer cells exhibit. Jasmonates are anticancer agents that interact directly with mitochondria. The aim of this study was to identify mitochondrial molecular targets of jasmonates. We report that jasmonates bind to hexokinase and detach it from the mitochondria and its mitochondrial anchor—the voltage-dependent anion channel (VDAC), as judged by hexokinase immunochemical and activity determinations, surface plasmon resonance analysis and planar lipid bilayer VDAC-activity analysis. Furthermore, the susceptibility of cancer cells and mitochondria to jasmonates is dependent on the expression of hexokinase, evaluated using hexokinase-overexpressing transfectants and its mitochondrial association. Many types of cancer cells exhibit overexpression of the key glycolytic enzyme, hexokinase, and its excessive binding to mitochondria. These characteristics are considered to play a pivotal role in cancer cell growth rate and survival. Thus, our findings provide an explanation for the selective effects of jasmonates on cancer cells. Most importantly, this is the first demonstration of a cytotoxic mechanism based on direct interaction between an anticancer agent and hexokinase. The proposed mechanism can serve to guide development of a new selective approach for cancer therapy.
- 1 March 2007
- Published by Wiley in British Journal of Pharmacology
- Vol. 150 (6) , 738-749
Effects of natural and novel synthetic jasmonates in experimental metastatic melanoma
Background and purpose: No current treatment reliably affects the course of metastatic melanoma. Consequently, novel approaches to the control of metastasis are actively sought. The overall goal of the present study was to identify new anti‐metastatic agents active against melanoma cells.Experimental approach: Two directions were taken: 1. To determine whether the natural plant hormone methyl jasmonate, which kills cancer cells selectively, can suppress the characteristic metastatic behavior of B16‐F10 melanoma cells; 2. To synthesize and identify novel jasmonate derivatives with better cytotoxic and anti‐metastatic activities than methyl jasmonate.Key results: We found that methyl jasmonate suppressed B16‐F10 cell motility and inhibited the development of experimental lung metastases of these cells. Furthermore, methyl jasmonate suppressed the motility of a sub‐clone of these cells over‐expressing P‐glycoprotein and exhibiting multidrug resistance. The synthetic derivative Compound I (5,7,9,10‐tetrabromo derivative of methyl jasmonate, the most active derivative) had greater cytotoxic potency (IC50, 0.04mM) than methyl jasmonate (IC50, 2.6mM). Compound I prevented B16‐F10 cell adhesion efficiently and inhibited the development of lung metastases at a much lower dose than methyl jasmonate.Conclusions and Implications: Natural and synthetic jasmonates have anti‐metastatic actions. Further development of these agents for the suppression of metastasis in melanoma and other types of cancer is warranted.British Journal of Pharmacology (2007) 150, 738–749. doi:10.1038/sj.bjp.0707146
- 1 March 2007
- Published by Wiley in British Journal of Pharmacology
- Vol. 150 (6) , 738-749
Effects of natural and novel synthetic jasmonates in experimental metastatic melanoma
Background and purpose: No current treatment reliably affects the course of metastatic melanoma. Consequently, novel approaches to the control of metastasis are actively sought. The overall goal of the present study was to identify new anti‐metastatic agents active against melanoma cells.Experimental approach: Two directions were taken: 1. To determine whether the natural plant hormone methyl jasmonate, which kills cancer cells selectively, can suppress the characteristic metastatic behavior of B16‐F10 melanoma cells; 2. To synthesize and identify novel jasmonate derivatives with better cytotoxic and anti‐metastatic activities than methyl jasmonate.Key results: We found that methyl jasmonate suppressed B16‐F10 cell motility and inhibited the development of experimental lung metastases of these cells. Furthermore, methyl jasmonate suppressed the motility of a sub‐clone of these cells over‐expressing P‐glycoprotein and exhibiting multidrug resistance. The synthetic derivative Compound I (5,7,9,10‐tetrabromo derivative of methyl jasmonate, the most active derivative) had greater cytotoxic potency (IC50, 0.04mM) than methyl jasmonate (IC50, 2.6mM). Compound I prevented B16‐F10 cell adhesion efficiently and inhibited the development of lung metastases at a much lower dose than methyl jasmonate.Conclusions and Implications: Natural and synthetic jasmonates have anti‐metastatic actions. Further development of these agents for the suppression of metastasis in melanoma and other types of cancer is warranted.British Journal of Pharmacology (2007) 150, 738–749. doi:10.1038/sj.bjp.0707146
- 16 February 2007
- Published by Springer Nature in Journal of Bioenergetics and Biomembranes
- Vol. 39 (1) , 51-57
Mitochondria-mediated ATP depletion by anti-cancer agents of the jasmonate family
Jasmonates are plant stress hormones that induce suppression of proliferation and death in cancer cells, while being selectively inactive towards non-transformed cells. Jasmonates can overcome apoptotic blocks and exert cytotoxic effects on drug-resistant cells expressing p53 mutations. Jasmonates induce a rapid depletion of ATP in cancer cells. Indeed, this steep drop occurs when no signs of cell death are detectable yet. Experiments using modulators of ATP synthesis via glycolysis or oxidative phosphorylation suggest that the latter is the pathway suppressed by jasmonates. Consequently, the direct effects of jasmonates on mitochondria were evaluated. Jasmonates induced cytochrome c release and swelling in mitochondria isolated from cancer cells but not from normal ones. Thus, the selectivity of jasmonates against cancer cells is rooted at the mitochondrial level, and probably exploits differences between mitochondria from normal versus cancer cells. These findings position jasmonates as promising anti-cancer drugs acting via energetic depletion in neoplastic cells.
- 16 February 2007
- Published by Springer Nature in Journal of Bioenergetics and Biomembranes
- Vol. 39 (1) , 51-57
Mitochondria-mediated ATP depletion by anti-cancer agents of the jasmonate family
Jasmonates are plant stress hormones that induce suppression of proliferation and death in cancer cells, while being selectively inactive towards non-transformed cells. Jasmonates can overcome apoptotic blocks and exert cytotoxic effects on drug-resistant cells expressing p53 mutations. Jasmonates induce a rapid depletion of ATP in cancer cells. Indeed, this steep drop occurs when no signs of cell death are detectable yet. Experiments using modulators of ATP synthesis via glycolysis or oxidative phosphorylation suggest that the latter is the pathway suppressed by jasmonates. Consequently, the direct effects of jasmonates on mitochondria were evaluated. Jasmonates induced cytochrome c release and swelling in mitochondria isolated from cancer cells but not from normal ones. Thus, the selectivity of jasmonates against cancer cells is rooted at the mitochondrial level, and probably exploits differences between mitochondria from normal versus cancer cells. These findings position jasmonates as promising anti-cancer drugs acting via energetic depletion in neoplastic cells.
- 1 January 2007
- Published by Elsevier in Cancer Letters
- Vol. 245 (1-2) , 1-10
Jasmonates in cancer therapy
- 1 January 2007
- Published by Elsevier in Cancer Letters
- Vol. 245 (1-2) , 1-10
Jasmonates in cancer therapy